Literature DB >> 15106086

The theory of measles elimination: implications for the design of elimination strategies.

Nigel J Gay1.   

Abstract

The theory of disease transmission provides a consistent framework within which to design, evaluate, and monitor measles elimination programs. Elimination of measles requires maintaining the effective reproduction number R at <1, by achieving and maintaining low levels of susceptibility. The essential features of different vaccination strategies (e.g., routine versus campaigns, number of doses) can be compared within this framework. Designing an elimination program for a particular population involves setting target levels of susceptibility, establishing the current susceptibility profile, selecting an approach to reduce susceptibility below the target, and selecting an approach to maintain susceptibility below the target. A key indicator of the sustainability of an elimination program is the residual level of susceptibility of a cohort after it has completed its scheduled vaccination opportunities. This can be estimated from vaccination coverage data. The high transmissibility of measles poses a significant challenge to any attempt to eliminate it.

Mesh:

Substances:

Year:  2004        PMID: 15106086     DOI: 10.1086/381592

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

Review 2.  Biological feasibility of measles eradication.

Authors:  William J Moss; Peter Strebel
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

3.  Seroepidemiology of measles in Beijing, China: a cross-sectional study.

Authors:  Zhujiazi Zhang; Meng Chen; Yiting Wang; Juan Li; Xiaomei Li; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

4.  Reiteration of the elimination status of measles in the southeast of Iran, 2015.

Authors:  Shahrokh Izadi; Masoome Arabsalmani; Mahdi Mohammadi; Seyed Mehdi Tabatabaei; Ali-Akbar Haghdoost
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

5.  Optimization of interventions in ebola: differential contagion.

Authors:  Amesh A Adalja; D A Henderson
Journal:  Biosecur Bioterror       Date:  2014 Nov-Dec

6.  Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Authors:  Alessia Melegaro; Yoon Hong Choi; Robert George; W John Edmunds; Elizabeth Miller; Nigel J Gay
Journal:  BMC Infect Dis       Date:  2010-04-08       Impact factor: 3.090

7.  Identifying high-risk areas for sporadic measles outbreaks: lessons from South Africa.

Authors:  Benn Sartorius; C Cohen; T Chirwa; G Ntshoe; A Puren; K Hofman
Journal:  Bull World Health Organ       Date:  2013-01-11       Impact factor: 9.408

8.  Children and Adolescents Unvaccinated Against Measles: Geographic Clustering, Parents' Beliefs, and Missed Opportunities.

Authors:  Philip J Smith; Edgar K Marcuse; Jane F Seward; Zhen Zhao; Walter A Orenstein
Journal:  Public Health Rep       Date:  2015 Sep-Oct       Impact factor: 2.792

9.  Measles vaccination using a microneedle patch.

Authors:  Chris Edens; Marcus L Collins; Jessica Ayers; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2012-10-05       Impact factor: 3.641

10.  Health status of visitors and temporary residents, United States.

Authors:  Emad A Yanni; Nina Marano; William M Stauffer; Elizabeth D Barnett; Maria Cano; Martin S Cetron
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.